Spruce Biosciences
SPRB
49 hedge funds and large institutions have $14.1M invested in Spruce Biosciences in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 12 closing their positions.
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
32% more funds holding
Funds holding: 37 → 49 (+12)
0% more call options, than puts
Call options by funds: $39K | Put options by funds: $39K
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
85% less capital invested
Capital invested by funds: $94.4M → $14.1M (-$80.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$3.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.25M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$1.24M |
| 4 |
SCM
Superstring Capital Management
New York
|
+$1.09M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$860K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$19.7M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$6.93M |
| 3 |
AC
Armistice Capital
New York
|
-$6.53M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$6.33M |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$6.22M |
SPRB Hedge Fund Activity: Q1 2024 in Review
49 of the 6,947 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q1 2024, worth a combined $14.1M — down 85% from $94.4M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SPRB positions and 12 closed out — a net gain of 12 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.9M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $19.7M sold.
- 49 institutional investors held Spruce Biosciences (SPRB) as of Q1 2024, up from 37 in Q4 2023.
- Funds reported $14.1M of Spruce Biosciences stock for Q1 2024, down 85% quarter-over-quarter.
- 24 funds opened new Spruce Biosciences positions in Q1 2024 and 12 closed out, a net change of +12 holders.
- The largest Spruce Biosciences buyer in Q1 2024 was Altium Capital Management, an estimated $3.9M added.
- The largest Spruce Biosciences seller in Q1 2024 was Novo Holdings A/S, an estimated $19.7M sold.
Based on aggregated 13F filings for Q1 2024.